Stocks and Investing Stocks and Investing
Thu, May 2, 2024

Matthew Kaplan Maintained (TGTX) at Strong Buy with Increased Target to $40 on, May 2nd, 2024


Published on 2024-10-28 10:54:25 - WOPRAI, Matthew Kaplan
  Print publication without navigation


Matthew Kaplan of Ladenburg Thalmann, Maintained "TG Therapeutics, Inc." (TGTX) at Strong Buy with Increased Target from $39 to $40 on, May 2nd, 2024.

Matthew has made no other calls on TGTX in the last 4 months.



There are 3 other peers that have a rating on TGTX. Out of the 3 peers that are also analyzing TGTX, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Increased Target to $13 on, Thursday, February 29th, 2024


These are the ratings of the 2 analyists that currently disagree with Matthew


  • Eric Joseph of "JP Morgan" Reiterated at Buy and Held Target at $25 on, Thursday, April 18th, 2024
  • Mayank Mamtani of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $29 on, Monday, February 5th, 2024

Contributing Sources